Jeffrey G. Marblestone
About
In The Last Decade
Jeffrey G. Marblestone
11 papers receiving 571 citations
Peers
Comparison fields: 5 of 73
- Molecular Biology 515
- Oncology 141
- Genetics 81
- Radiology, Nuclear Medicine and Imaging 76
- Cell Biology 47
Countries citing papers authored by Jeffrey G. Marblestone
This map shows the geographic impact of Jeffrey G. Marblestone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey G. Marblestone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey G. Marblestone more than expected).
Fields of papers citing papers by Jeffrey G. Marblestone
This network shows the impact of papers produced by Jeffrey G. Marblestone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey G. Marblestone. The network helps show where Jeffrey G. Marblestone may publish in the future.
Co-authorship network of co-authors of Jeffrey G. Marblestone
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey G. Marblestone. A scholar is included among the top collaborators of Jeffrey G. Marblestone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey G. Marblestone. Jeffrey G. Marblestone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Ubiquitin ligase Idol Inhibitors for Treating Hypercholesterolemia | The FASEB Journal | Jeffrey G. Marblestone, Jian Wu et al. | 1 |
| 2 | Cancer Immunotherapy via Regulation of the Ubiquitin Proteasome Pathway | The FASEB Journal | Suresh Kumar, Jian Wu et al. | 1 |
| 3 | Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives | SLAS DISCOVERY | Benjamin Nicholson, Suresh Kumar et al. | 10 |
| 4 | Comprehensive Ubiquitin E2 Profiling of Ten Ubiquitin E3 Ligases | Cell Biochemistry and Biophysics | Jeffrey G. Marblestone, David E. Sterner et al. | 22 |
| 5 | Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins | Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | Jeffrey G. Marblestone, Michael R. Mattern et al. | 16 |
| 6 | Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy | Cell Biochemistry and Biophysics | Michael J. Eddins, Jeffrey G. Marblestone et al. | 46 |
| 7 | Novel Approach for Characterizing Ubiquitin E3 Ligase Function | SLAS DISCOVERY | Jeffrey G. Marblestone, Suresh Kumar et al. | 14 |
| 8 | Strategies for the identification of ubiquitin ligase inhibitors | Biochemical Society Transactions | Seth J. Goldenberg, Jeffrey G. Marblestone et al. | 27 |
| 9 | Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference. | PubMed | Jeffrey G. Marblestone | 2 |
| 10 | Deubiquitinating Enzymes as Novel Anticancer Targets | Future Oncology | Benjamin Nicholson, Jeffrey G. Marblestone et al. | 99 |
| 11 | Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO | Protein Science | Jeffrey G. Marblestone, Suzanne C. Edavettal et al. | 369 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.